Through a weekly podcast, they strive to keep the listeners informed of the new technology and treatments available. Their mission is to notify the listener of rapid discoveries as they become available. The podcast highlights the breakthrough technology for the study of medical research. Check Oncotarget at scimagojr.com
Oncotarget is a magazine that is designed by its peers and is dedicated to a weekly medical journal. It was established in 2010 to research oncology. Oncology is the study of the treatment of tumors or other medical related issues to include different types of cancer.
Through more research, they have shown that the breast cancer cells have several types of hormone receptors for estrogen. They have also found progesterone which contributes the function and growth. 15 percent of those with breast cancer has triple negative breast cancer (TNBC). With TNBC patients, they have a poor prognosis. It is because it could move to other parts of the body, in dispute of the advanced treatment methods available. Researchers are aiming to continue the extensive research get a better understanding of cancer. With a better understand, they may be able to find a better way to fight the disease.
They have found TNB cells lacked estrogen receptor alpha. As they continue to test on the subject, there is a significant slowing with estrogen-like chemicals. Data reveals that tumor-suppressive effects in triple negative breast cancer are controlled by regulating protein cell. Thus, suggesting the targeting protein will lead to new and useful therapies. Learn more about Oncotarget at Eurekalert.org.
There have been other studies that were observed in the patients who have TNBC, lacking Era, although they do have ERb. These patients tend to have a higher survival rate. Plus, they are also more likely to be cancer free. With this information drugs such as estrogen can provide a therapeutic benefit for these types of patients.
During these preliminary results, there will need to have more evaluations in cellular and animal models. It is to be done before they can be considered for clinical trials, which is a job that teams expect to continue with further studies. As they continue to research breast cancer, the cure continues to be more clear.